Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 34Cisplatin 30Brachytherapy 16Paclitaxel 15Carboplatin 15Bevacizumab 15Radiotherapy 14Blood Specimen Collection 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Colposcopy 11Nivolumab 10Drug Therapy 10atezolizumab 8Human Papillomavirus DNA Tests 8Gemcitabine 8lenvatinib 7Radiation 6Platinum 6Biopsy 6toripalimab 5cemiplimab 5Surveys and Questionnaires 5Standard of Care 5Radiotherapy, Intensity-Modulated 5Practice Guidelines as Topic 5Patient Navigation 5Methods 5Fulvestrant 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × BAY 1895344 × 1 year × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡